Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,135.95
(
-0.04%
)
US TECH 100
26,462.80
(
0.00%
)
Dow Jones
48,861.81
(
-0.57%
)
Brent Oil
111.79
(
-0.53%
)
Bitcoin
76,009.56
(
0.31%
)
News Focus
News Focus
Post# of 257470
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122909
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 245650

Tuesday, 02/28/2023 5:49:57 PM

Tuesday, February 28, 2023 5:49:57 PM

Post# of 257470
PFE’s RSV vaccine_for_adults_60+_endorsed_by VRBPAC in_dual 7-4 votes_on_safety_and_efficacy:

https://finance.yahoo.com/news/pfizer-receives-positive-fda-advisory-214000244.html

The crux of the matter for the panel was whether the Guillain-Barre risk warrants another pre-approval trial or whether a post-approval trial, which PFE has consented to run, is sufficient.

PFE’s PDUFA date is 5/31/23.

VRBPAC debates GSK’s RSV vaccine tomorrow. (GSK has a PDUFA date of 5/3/23.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today